Home Neoplasma Ahead of print Neoplasma Vol.66, No.2, p.301-307, 2019

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.66, No.2, p.301-307, 2019

Title: Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens
Author: L. Qian, Y. B. Dong, L. L. Zhao, H. J. Zhao, J. W. Cui, N. Wang

Abstract: A score model based on clinical characteristics in advanced hepatocellular carcinoma (HCC) patients treated with systemic chemotherapy of oxaliplatin-containing regimens was established to evaluate progression-free survival (PFS) and overall survival (OS). Thirty HCC patients eligible for radical resection were involved in the retrospective study, and these were divided into the good response group (complete response (CR)/partial response (PR) and the poor response group (stable disease (SD)/progression disease (PD). The median PFS and OS were compared in the two groups. PFS and OS combined with clinical characteristics were evaluated by univariate and multivariate analyses. The score model was defined with 1 score for each characteristic, and score model cut-off values were determined by the receiver operating characteristic curve (ROC) which describes treatment response. The median PFS was 10 and 2 months (p

Keywords: oxaliplatin-containing regimen, HCC patients, progression-free survival (PFS), overall survival (OS), score model
Published online: 19-Mar-2019
Year: 2019, Volume: 66, Issue: 2 Page From: 301, Page To: 307
doi:10.4149/neo_2018_180706N448


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.